selected publications
- An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Expert review of anticancer therapy. 2024 Review GET IT
- Gene Signature for Predicting Metastasis in Prostate Cancer Using Primary Tumor Expression Profiles. 2024 GET IT
- Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients. European journal of nuclear medicine and molecular imaging. 2024 Academic Article GET IT
- Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study. European urology open science. 2024 Academic Article GET IT
-
Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.
International journal of molecular sciences.
2023
Review
GET IT
Times cited: 7 - Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer. Journal of translational medicine. 2023 Academic Article GET IT
- Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial. ESMO open. 2023 Academic Article GET IT
-
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer.
International journal of molecular sciences.
2023
Academic Article
GET IT
Times cited: 1 -
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer.
Cancers.
2023
Review
GET IT
Times cited: 28 -
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors.
Frontiers in immunology.
2023
Review
GET IT
Times cited: 11 -
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer.
Cancers.
2022
Review
GET IT
Times cited: 3 -
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment.
Frontiers in oncology.
2022
Review
GET IT
Times cited: 20 -
Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer.
Frontiers in oncology.
2022
Review
GET IT
Times cited: 4 -
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma.
Targeted oncology.
2021
Academic Article
GET IT
Times cited: 64 -
Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications.
Cancers.
2021
Review
GET IT
Times cited: 10 -
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients.
International journal of cancer.
2021
Academic Article
GET IT
Times cited: 8 -
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma.
Frontiers in oncology.
2021
Academic Article
GET IT
Times cited: 9 -
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA.
Expert review of molecular diagnostics.
2021
Review
GET IT
Times cited: 4 -
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review.
International journal of molecular sciences.
2021
Academic Article
GET IT
Times cited: 2